These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

472 related articles for article (PubMed ID: 15474365)

  • 41. In vivo gene delivery of glial cell line--derived neurotrophic factor for Parkinson's disease.
    Kordower JH
    Ann Neurol; 2003; 53 Suppl 3():S120-32; discussion S132-4. PubMed ID: 12666104
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Studies on neuroprotective and regenerative effects of GDNF in a partial lesion model of Parkinson's disease.
    Björklund A; Rosenblad C; Winkler C; Kirik D
    Neurobiol Dis; 1997; 4(3-4):186-200. PubMed ID: 9361295
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Differential cytotoxicity of human wild type and mutant alpha-synuclein in human neuroblastoma SH-SY5Y cells in the presence of dopamine.
    Moussa CE; Wersinger C; Tomita Y; Sidhu A
    Biochemistry; 2004 May; 43(18):5539-50. PubMed ID: 15122920
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Progressive neurodegenerative and behavioural changes induced by AAV-mediated overexpression of α-synuclein in midbrain dopamine neurons.
    Decressac M; Mattsson B; Lundblad M; Weikop P; Björklund A
    Neurobiol Dis; 2012 Mar; 45(3):939-53. PubMed ID: 22182688
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Dopamine transporter-mediated cytotoxicity of 6-hydroxydopamine in vitro depends on expression of mutant alpha-synucleins related to Parkinson's disease.
    Lehmensiek V; Tan EM; Liebau S; Lenk T; Zettlmeisl H; Schwarz J; Storch A
    Neurochem Int; 2006 Apr; 48(5):329-40. PubMed ID: 16406146
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Alpha-synuclein aggregation and cell death triggered by energy deprivation and dopamine overload are counteracted by D2/D3 receptor activation.
    Bellucci A; Collo G; Sarnico I; Battistin L; Missale C; Spano P
    J Neurochem; 2008 Jul; 106(2):560-77. PubMed ID: 18410503
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Lentiviral vector delivery of parkin prevents dopaminergic degeneration in an alpha-synuclein rat model of Parkinson's disease.
    Lo Bianco C; Schneider BL; Bauer M; Sajadi A; Brice A; Iwatsubo T; Aebischer P
    Proc Natl Acad Sci U S A; 2004 Dec; 101(50):17510-5. PubMed ID: 15576511
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Reversible neurochemical changes mediated by delayed intrastriatal glial cell line-derived neurotrophic factor gene delivery in a partial Parkinson's disease rat model.
    Yang X; Mertens B; Lehtonen E; Vercammen L; Bockstael O; Chtarto A; Levivier M; Brotchi J; Michotte Y; Baekelandt V; Sarre S; Tenenbaum L
    J Gene Med; 2009 Oct; 11(10):899-912. PubMed ID: 19639608
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Towards a neuroprotective gene therapy for Parkinson's disease: use of adenovirus, AAV and lentivirus vectors for gene transfer of GDNF to the nigrostriatal system in the rat Parkinson model.
    Björklund A; Kirik D; Rosenblad C; Georgievska B; Lundberg C; Mandel RJ
    Brain Res; 2000 Dec; 886(1-2):82-98. PubMed ID: 11119690
    [TBL] [Abstract][Full Text] [Related]  

  • 50. GDNF applied to the MPTP-lesioned nigrostriatal system requires TGF-beta for its neuroprotective action.
    Schober A; Peterziel H; von Bartheld CS; Simon H; Krieglstein K; Unsicker K
    Neurobiol Dis; 2007 Feb; 25(2):378-91. PubMed ID: 17141511
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Self-inactivating lentiviral vectors with enhanced transgene expression as potential gene transfer system in Parkinson's disease.
    Déglon N; Tseng JL; Bensadoun JC; Zurn AD; Arsenijevic Y; Pereira de Almeida L; Zufferey R; Trono D; Aebischer P
    Hum Gene Ther; 2000 Jan; 11(1):179-90. PubMed ID: 10646649
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Encapsulated cell biodelivery of GDNF: a novel clinical strategy for neuroprotection and neuroregeneration in Parkinson's disease?
    Lindvall O; Wahlberg LU
    Exp Neurol; 2008 Jan; 209(1):82-8. PubMed ID: 17963752
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Silencing of human alpha-synuclein in vitro and in rat brain using lentiviral-mediated RNAi.
    Sapru MK; Yates JW; Hogan S; Jiang L; Halter J; Bohn MC
    Exp Neurol; 2006 Apr; 198(2):382-90. PubMed ID: 16455076
    [TBL] [Abstract][Full Text] [Related]  

  • 54. [Growth factors as neuroprotective treatment in Parkinson disease?].
    Torp R; Singh PB; Sørensen DR; Dietrichs E; Hirschberg H
    Tidsskr Nor Laegeforen; 2006 Mar; 126(7):899-901. PubMed ID: 16554879
    [TBL] [Abstract][Full Text] [Related]  

  • 55. HSV vector-delivery of GDNF in a rat model of PD: partial efficacy obscured by vector toxicity.
    Monville C; Torres E; Thomas E; Scarpini CG; Muhith J; Lewis J; Finn J; Smith C; Cai S; Efstathiou S; Howard K; Dunnett SB
    Brain Res; 2004 Oct; 1024(1-2):1-15. PubMed ID: 15451362
    [TBL] [Abstract][Full Text] [Related]  

  • 56. A glial cell line-derived neurotrophic factor (GDNF):tetanus toxin fragment C protein conjugate improves delivery of GDNF to spinal cord motor neurons in mice.
    Larsen KE; Benn SC; Ay I; Chian RJ; Celia SA; Remington MP; Bejarano M; Liu M; Ross J; Carmillo P; Sah D; Phillips KA; Sulzer D; Pepinsky RB; Fishman PS; Brown RH; Francis JW
    Brain Res; 2006 Nov; 1120(1):1-12. PubMed ID: 17020749
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Comparison of the capability of GDNF, BDNF, or both, to protect nigrostriatal neurons in a rat model of Parkinson's disease.
    Sun M; Kong L; Wang X; Lu XG; Gao Q; Geller AI
    Brain Res; 2005 Aug; 1052(2):119-29. PubMed ID: 16018990
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Kinetic stabilization of the alpha-synuclein protofibril by a dopamine-alpha-synuclein adduct.
    Conway KA; Rochet JC; Bieganski RM; Lansbury PT
    Science; 2001 Nov; 294(5545):1346-9. PubMed ID: 11701929
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Adenovirus-mediated glial cell line-derived neurotrophic factor (GDNF) expression protects against subsequent cortical cold injury in rats.
    Hermann DM; Kilic E; Kügler S; Isenmann S; Bähr M
    Neurobiol Dis; 2001 Dec; 8(6):964-73. PubMed ID: 11741392
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Alterations in lysosomal and proteasomal markers in Parkinson's disease: relationship to alpha-synuclein inclusions.
    Chu Y; Dodiya H; Aebischer P; Olanow CW; Kordower JH
    Neurobiol Dis; 2009 Sep; 35(3):385-98. PubMed ID: 19505575
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 24.